Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up
SHANGHAI and HONG KONG, March 21, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2024, along with several significant milestones achieved in recent months. Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, stated, "To Antengene, 2024 was indeed an extraordinary year...
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced a global strategic collaboration with AstraZeneca to discover and develop next-generation multi-specific antibodies for immunology, oncology and beyond. The...
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data...
Akeso’s Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting
HONG KONG, March 21, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab (AK104), in combination with concurrent chemoradiotherapy (CCRT) for the treatment of locally advanced cervical cancer....
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation...
WuXi Biologics Named to CDP Water Security “A List” for Second Consecutive Year
Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 21, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it...
VISTA Eye Specialist Expands ESG Commitment with Sponsorship of Destiny Football Development Centre to Empower Youth Through Sports and Vision
PETALING JAYA, Malaysia, March 21, 2025 /PRNewswire/ -- VISTA Eye Specialist, Malaysia's leading eye care provider, proudly announces its sponsorship of Destiny Football Development Centre (Destiny FDC) as part of its continued commitment to Environmental, Social, and Governance (ESG) initiatives. This strategic partnership focuses on youth development, community engagement, and health awareness, reinforcing VISTA's purpose-driven mission to improve lives...
Wounds hard to heal? Troubled by dressing changes? Dimora, Amazon’s 3-year top brand, shows you the way.
NEW YORK, March 21, 2025 /PRNewswire/ -- Dimora Medical, a continuous innovator in high-end medical care supplies, has secured the number one spot in Amazon's Wound Dressings category for the third year. With over 33 million wound dressings sold since its 2019 debut, Dimora Medical continues to dominate amidst fierce competition from other renowned brands in the wound dressing...
Noul Showcases AI-Powered Cervical Cancer Cell Screening Technology at NVIDIA GTC 2025
Company Joins NVIDIA Healthcare & Life Sciences (HCLS) Ecosystem to Advance Global Diagnostic Accessibility and Seeks Partnerships with Global Healthcare Opportunities YONGIN, South Korea, March 21, 2025 /PRNewswire/ -- Noul Co., Ltd. a Korea-based medical AI company, announced that it presented a poster titled "Bridging Medical Gaps from Malaria to Cancer: On-Device...
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world VisualDx's system seeks to enhance identification of people who may have BPDCN, leveraging actual images of BPDCN skin lesions and...
